TCR-transduced CD8⁺ T cells efficiently lyse primary B-cell malignancies, including MM. (A-B) T-cell clone 4G11 or purified TCR- or mock-transduced CD8⁺ T cells were tested for their lytic capacity of HLA-B7⁺ target cells. PKH-labeled target cells were cocultured at various effector-to-target ratios with effector T cells. After 18 hours of coculture, the number of live targets cells was assessed by flow cytometry, and percent survival was calculated. (A) Malignant cell samples included MM cell line UM9, primary MM, MCL, ALL, and CLL. Controls included BOB1⁻ cell line K562-B7. (B) Healthy hematopoietic cells were of the same origin as transduced T cells (autologous setting) and included phytohemagglutinin-activated T cells, CD14⁺ monocytes, CD19⁺ primary B cells, and CD40L-activated B cells. Shown are means with standard deviations of 1 experiment carried out in triplicate.